Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02229929 · ClinicalTrials.gov registry record · Phase 2
Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT02229929: Completed Phase 2 study, sponsored by Cara Therapeutics.
NCT02229929 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 89 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02229929, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The primary purpose of this study is to: * Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week in patients who are undergoing hemodialysis. (Part A) * This study is also investigating whether repeated doses of IV CR845 over two weeks is safe and effective in reducing the intensity of itching in hemodialysis patients with uremic pruritus (Part B).
Primary Outcome
To evaluate the pharmacokinetics of repeated doses of CR845 in hemodialysis patients over a one-week treatment period.
Interventions
- DRUG Part A: Placebo
- DRUG Part A: CR845 0.5 mcg/kg
- DRUG Part A: CR845 1.0 mcg/kg
- DRUG Part A: CR845 2.5 mcg/kg
- DRUG Part B: Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 2 |
What the finished NCT02229929 record still lists
NCT02229929 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 5 interventions - of which Part A: Placebo is the first listed.
NCT02229929 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02229929 about?
NCT02229929 is a clinical study titled "Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus". The primary purpose of this study is to: * Evaluate the safety and pharmacokinetic profile of repeated doses IV CR845 over one week in patients who are undergoing hemodialysis. (Part A) * This study is also investigating whether repeated doses of IV CR845 over two weeks is safe and effective in red...
What is the current status of trial NCT02229929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2014-07. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02229929?
The interventions under investigation include: Part A: Placebo (DRUG), Part A: CR845 0.5 mcg/kg (DRUG), Part A: CR845 1.0 mcg/kg (DRUG), Part A: CR845 2.5 mcg/kg (DRUG), Part B: Placebo (DRUG).
Who is sponsoring clinical trial NCT02229929?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02229929's enrollment target sits among peer trials
89 802nd of 2000 higher than 1,198 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03682289 · 89 participants · Phase 2
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
- NCT04787939 · 89 participants · NA
Early Feeding After Oral Cavity Reconstruction
- NCT05480449 · 89 participants · Phase 1
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
- NCT05604131 · 89 participants · Phase 2
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia